GOVX GeoVax Labs, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 832489 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-84.8%
TTM net income YoY12.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,523.4%
Net margin-2,507.3%
FCF margin-2,236.0%
EBITDA margin-2,515.9%
Returns
ROE-509.3%
ROA-309.3%
ROIC (approx.)—
Asset turnover0.12x
Leverage & solvency
Liabilities / assets83.4%
Debt / equity0.00x
Current ratio1.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-33.6%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.49M | $3.95M | $0 | $81,526 | $385,501 |
| R&D expense | $18.12M | $23.71M | $20.72M | $9.12M | $15.55M |
| SG&A expense | $6.01M | $5.39M | $6.02M | $4.99M | $3.58M |
| Operating income | -$21.64M | -$25.14M | -$26.74M | -$14.03M | -$18.75M |
| Interest expense | $0 | $21,375 | $0 | $0 | $1,286 |
| Income tax | — | — | — | — | $0 |
| Net income | -$21.46M | -$24.99M | -$25.97M | -$14.02M | -$18.57M |
| EBITDA | -$21.57M | -$25.05M | -$26.67M | -$13.97M | -$18.71M |
| EPS (basic) | -22.40 | -120.46 | -14.29 | -12.39 | -3.04 |
| EPS (diluted) | — | — | — | — | -3.04 |
| Weighted avg. shares (diluted) | — | — | — | — | 6.10M |
| Balance sheet | |||||
| Cash & equivalents | $3.09M | $5.51M | $6.45M | $27.61M | $11.42M |
| Receivables | $0 | $659,409 | $0 | — | — |
| Current assets | $5.31M | $7.93M | $7.89M | $28.94M | $11.63M |
| PP&E, net | $108,830 | $149,974 | $209,689 | $234,912 | $156,938 |
| Total assets | $6.34M | $8.16M | $9.28M | $31.35M | $11.80M |
| Current liabilities | $1.94M | $3.11M | $3.52M | $4.75M | $5.44M |
| Total liabilities | $2.52M | $3.11M | $3.52M | $4.75M | $7.44M |
| Shareholders' equity | $3.83M | $5.05M | $5.76M | $26.60M | $4.36M |
| Shares outstanding | 72,173 | 421,475 | 1.98M | 1.76M | 6.38M |
| Cash flow statement | |||||
| Operating cash flow | -$21.47M | -$24.68M | -$25.17M | -$19.03M | -$11.20M |
| Capital expenditure | $27,612 | $20,653 | $48,946 | $134,258 | $47,718 |
| Free cash flow | -$21.50M | -$24.70M | -$25.22M | -$19.16M | -$11.24M |
| Investing cash flow | -$27,612 | -$20,653 | -$48,946 | -$134,258 | -$47,718 |
| Financing cash flow | $19.08M | $23.75M | $4.06M | $35.35M | $12.78M |
| Depreciation & amortization | $68,756 | $95,368 | $74,169 | $56,284 | $38,521 |
| Stock-based compensation | $1.12M | $528,644 | $1.07M | $902,074 | $369,987 |
Free plan shows the latest 5 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.